Literature DB >> 17587187

Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction.

Hirohisa Tsukamoto1, Kiyosumi Shibata, Hiroaki Kajiyama, Mikio Terauchi, Akihiro Nawa, Fumitaka Kikkawa.   

Abstract

The incidence of lymph node metastasis by endometrial carcinoma (EMCA) increases with the depth of myometrial invasion, and this depth of invasion has been found to have a major impact on the outcome. In the present study, we assessed the effect of tumor-stromal interactions on the invasive behavior of EMCA cells and examined the involvement of SDF-1alpha/CXCL12-CXCR4 in the interaction of EMCA cells and uterine smooth muscle cells (UtSMCs). We investigated whether SDF-1alpha/CXCL12 produced and secreted from UtSMCs induces EMCA cell migration by using 5 human EMCA cell lines such as AMEC and RL95 cells. The SDF-1alpha/CXCL12 concentration in conditioned medium (CM) of UtSMCs(was 4,120 +/- 530 pg/ml. Treatments with CM of UtSMCs and plated UtSMCs significantly induced both AMEC and RL95 cell migration. The induced cell migrations were significantly inhibited by CXCR4 mAb (12G5) and CXCR4 antagonist (AMD3100) pre-treatments. Treatments with UtSMCs CM to AMEC and RL95 cells stimulated Akt phosphorylation in a time-dependent manner. Pre-treatment of AMEC and RL95 cells with wortmannin as a PI3K inhibitor significantly inhibited UtSMCs CM-induced cell migration. The SDF-1alpha/CXCL12-CXCR4 chemokine axis between UtSMCs and EMCA played an important role in the muscular infiltration of endometrial cancer through activation of PI3K-Akt signaling pathway. Suppression of this pathway could be an effective target for the treatment of early uterine body cancer in particular.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587187     DOI: 10.1007/s10585-007-9079-5

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  32 in total

Review 1.  A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection.

Authors:  T Nagasawa; K Tachibana; T Kishimoto
Journal:  Semin Immunol       Date:  1998-06       Impact factor: 11.130

2.  CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.

Authors:  Francesco Bertolini; Chiara Dell'Agnola; Patrizia Mancuso; Cristina Rabascio; Alessandra Burlini; Silvia Monestiroli; Alberto Gobbi; Giancarlo Pruneri; Giovanni Martinelli
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

3.  A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma.

Authors:  H Geminder; O Sagi-Assif; L Goldberg; T Meshel; G Rechavi; I P Witz; A Ben-Baruch
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

4.  Cancer statistics, 2002.

Authors:  Ahmedin Jemal; Andrea Thomas; Taylor Murray; Michael Thun
Journal:  CA Cancer J Clin       Date:  2002 Jan-Feb       Impact factor: 508.702

5.  Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.

Authors:  Julie M Hall; Kenneth S Korach
Journal:  Mol Endocrinol       Date:  2003-02-13

6.  Chemokines and the arrest of lymphocytes rolling under flow conditions.

Authors:  J J Campbell; J Hedrick; A Zlotnik; M A Siani; D A Thompson; E C Butcher
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

7.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors.

Authors:  Joshua B Rubin; Andrew L Kung; Robyn S Klein; Jennifer A Chan; YanPing Sun; Karl Schmidt; Mark W Kieran; Andrew D Luster; Rosalind A Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

8.  Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells.

Authors:  Takashi Murakami; Wusi Maki; Adela R Cardones; Hui Fang; Adrian Tun Kyi; Frank O Nestle; Sam T Hwang
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

9.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.

Authors:  K Tachibana; S Hirota; H Iizasa; H Yoshida; K Kawabata; Y Kataoka; Y Kitamura; K Matsushima; N Yoshida; S Nishikawa; T Kishimoto; T Nagasawa
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

10.  Molecular cloning and structure of a pre-B-cell growth-stimulating factor.

Authors:  T Nagasawa; H Kikutani; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

View more
  10 in total

1.  Chemokines and Cancer Progression: A Qualitative Review on the Role of Stromal Cell-derived Factor 1-alpha and CXCR4 in Endometrial Cancer.

Authors:  Ashley S Felix; Robert Edwards; Robert Bowser; Faina Linkov
Journal:  Cancer Microenviron       Date:  2010-02-26

Review 2.  CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.

Authors:  F Guo; Y Wang; J Liu; S C Mok; F Xue; W Zhang
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

3.  Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression.

Authors:  Ashley S Felix; Roslyn A Stone; Mamatha Chivukula; Robert Bowser; Anil V Parwani; Faina Linkov; Robert P Edwards; Joel L Weissfeld
Journal:  Int J Cancer       Date:  2012-01-03       Impact factor: 7.396

4.  Biomarkers Associated with Lymph Nodal Metastasis in Endometrioid Endometrial Carcinoma.

Authors:  Mathilde Mairé; Aurélien Bourdon; Isabelle Soubeyran; Carlo Lucchesi; Frédéric Guyon; Guillaume Babin; Anne Floquet; Adeline Petit; Jessica Baud; Valérie Velasco; Denis Querleu; Sabrina Croce
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

5.  Endometrial Tumour Microenvironment.

Authors:  Carlos Casas-Arozamena; Miguel Abal
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  CXCL12/CXCR4 axis induces proliferation and invasion in human endometrial cancer.

Authors:  Pingping Liu; Ping Long; Yu Huang; Fengyi Sun; Zhenyan Wang
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

7.  Inhibition of CXCR4 and CXCR7 for reduction of cell proliferation and invasion in human endometrial cancer.

Authors:  Ping Long; Fengyi Sun; Yingying Ma; Yu Huang
Journal:  Tumour Biol       Date:  2015-12-17

8.  The CXCR4/CXCL12 axis in endometrial cancer.

Authors:  Stefania Gelmini; Monica Mangoni; Francesca Castiglione; Cristina Beltrami; Annalisa Pieralli; Karin Louise Andersson; Massimiliano Fambrini; Gian Luigi Taddei; Mario Serio; Claudio Orlando
Journal:  Clin Exp Metastasis       Date:  2009-02-06       Impact factor: 5.150

9.  Stromal derived factor-1 (SDF-1) and its receptors CXCR4 and CXCR7 in endometrial cancer patients.

Authors:  Malgorzata Walentowicz-Sadlecka; Pawel Sadlecki; Magdalena Bodnar; Andrzej Marszalek; Pawel Walentowicz; Alina Sokup; Arnika Wilińska-Jankowska; Marek Grabiec
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

10.  Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.

Authors:  Fei Teng; Wen-Yan Tian; Ying-Mei Wang; Yan-Fang Zhang; Fei Guo; Jing Zhao; Chao Gao; Feng-Xia Xue
Journal:  J Hematol Oncol       Date:  2016-02-06       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.